Cytek Biosciences, Inc.
CTKB
$3.71
$0.195.40%
| Weiss Ratings | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.19 | |||
| Price History | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -7.02% | |||
| 30-Day Total Return | -17.37% | |||
| 60-Day Total Return | -34.68% | |||
| 90-Day Total Return | -43.19% | |||
| Year to Date Total Return | -43.53% | |||
| 1-Year Total Return | -41.11% | |||
| 2-Year Total Return | -61.15% | |||
| 3-Year Total Return | -63.88% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -53.87% | |||
| 52-Week Low % Change | 7.65% | |||
| Price | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $7.63 | |||
| 52-Week Low Price | $3.27 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Nov 07, 2024 | |||
| Valuation | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 450.90M | |||
| Enterprise Value | 190.06M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.05 | |||
| Earnings Per Share Growth | -43.65% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.27 | |||
| Price/Book (Q) | 1.15 | |||
| Enterprise Value/Revenue (TTM) | 0.95 | |||
| Price | $3.71 | |||
| Enterprise Value/EBITDA (TTM) | -11.95 | |||
| Enterprise Value/EBIT | -8.22 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 129.08M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 877 922 9835 | |||
| Address | 47215 Lakeview Boulevard Fremont, CA 94538 | |||
| Website | cytekbio.com | |||
| Country | United States | |||
| Year Founded | 1992 | |||
| Profitability | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -11.53% | |||
| Profit Margin | -3.00% | |||
| Management Effectiveness | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -2.91% | |||
| Return on Equity | -- | |||
| Income Statement | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 200.45M | |||
| Total Revenue (TTM) | 200.45M | |||
| Revenue Per Share | $1.55 | |||
| Gross Profit (TTM) | 111.11M | |||
| EBITDA (TTM) | -15.91M | |||
| EBIT (TTM) | -23.12M | |||
| Net Income (TTM) | -6.02M | |||
| Net Income Avl. to Common (TTM) | -6.02M | |||
| Total Revenue Growth (Q YOY) | -1.30% | |||
| Earnings Growth (Q YOY) | 75.23% | |||
| EPS Diluted (TTM) | -0.05 | |||
| EPS Diluted Growth (Q YOY) | 73.48% | |||
| Balance Sheet | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 277.86M | |||
| Cash Per Share (Q) | $2.15 | |||
| Total Current Assets (Q) | 396.45M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 395.74M | |||
| Current Ratio (Q) | 5.859 | |||
| Book Value Per Share (Q) | $3.06 | |||
| Total Assets (Q) | 499.50M | |||
| Total Current Liabilities (Q) | 67.66M | |||
| Total Debt (Q) | 17.02M | |||
| Total Liabilities (Q) | 103.76M | |||
| Total Common Equity (Q) | 395.74M | |||
| Cash Flow | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -82.97M | |||
| Cash from Financing (TTM) | -15.82M | |||
| Net Change in Cash (TTM) | -68.89M | |||
| Levered Free Cash Flow (TTM) | 35.82M | |||
| Cash from Operations (TTM) | 25.38M | |||
